Mestrolyst 80 Tablet contains Megestrol acetate 80 mg, a synthetic progestin with potent antineoplastic and appetite-stimulating properties. It is primarily indicated for the palliative treatment of advanced breast cancer and endometrial carcinoma in postmenopausal women. Megestrol exerts its therapeutic effects by modulating hormonal activity, thereby inhibiting the growth of hormone-sensitive tumor cells. Additionally, Mestrolyst 80 is utilized to manage anorexia, cachexia, or significant weight loss in patients with chronic illnesses such as cancer or AIDS, enhancing appetite and promoting weight gain. The tablet should be administered orally, with dosage individualized based on the patient’s clinical condition and response. Common adverse effects include weight gain, edema, thromboembolic events, and gastrointestinal disturbances. Caution is advised in patients with a history of thromboembolism, cardiovascular disease, or hepatic impairment. Regular monitoring of liver function and coagulation parameters is recommended during prolonged therapy. Mestrolyst 80 is contraindicated in pregnancy and in patients with known hypersensitivity to Megestrol or any tablet excipients. It is essential to use this medication under strict medical supervision to optimize therapeutic outcomes and minimize potential risks.